Zobrazeno 1 - 10
of 203
pro vyhledávání: '"Hisateru Yasui"'
Autor:
Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Shogen Boku, Toshihiro Kudo, Yoshiyuki Yamamoto, Akiyoshi Kanazawa, Tadamichi Denda, Masahiro Goto, Naoko Iida, Hiroshi Ozaki, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Yoichi Naito, Takayuki Yoshino
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-10 (2024)
Abstract Background While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of
Externí odkaz:
https://doaj.org/article/8d89e02235024fa88d2552871e8438cb
Autor:
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract “NeoRAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequen
Externí odkaz:
https://doaj.org/article/32159db2ff3a4f6f8eaee8f39adf3f96
Autor:
Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ikeda
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 8, Iss 2, Pp 132-136 (2024)
Background: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs); acq
Externí odkaz:
https://doaj.org/article/3c42bc614e4e45ca97f85e629c86cea8
Autor:
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake, Atsuo Takashima, Nobuhisa Matsuhashi, Takeshi Kato, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18702-18716 (2023)
Abstract Background Several biomarkers have been established for metastatic colorectal cancer (mCRC). We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first‐line (1L) treatmen
Externí odkaz:
https://doaj.org/article/3ebebc37f7d94a9b970dc82f9c2f0539
Autor:
Toshihiko Matsumoto, Tatsuki Ikoma, Shogo Yamamura, Kou Miura, Takao Tsuduki, Takanori Watanabe, Hiroki Nagai, Masahiro Takatani, Hisateru Yasui
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the effica
Externí odkaz:
https://doaj.org/article/a9e301dfe6fd46189cdfb7cbe6561053
Autor:
Toshihiko Matsumoto, Tatsuki Ikoma, Shogo Yamamura, Kou Miura, Takao Tsuduki, Takanori Watanabe, Hiroki Nagai, Masahiro Takatani, Hisateru Yasui
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/7c46308326ce40549021fb815b9358e6
Autor:
Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Tomoyo Yasuda, Shogen Boku, Takashi Kawai, Nobuhiro Shibata, Hiroki Nagai, Takao Tsuduki, Takanobu Shimada, Yusuke Matsumoto, Takehiko Tsumura, Masahiro Takatani, Hisateru Yasui, Hironaga Satake
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 16 (2022)
Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effect
Externí odkaz:
https://doaj.org/article/6d5c257c05f04838a9c61c5e4a6e0026
Autor:
Shunsuke A. Sakai, Masato Aoshima, Kentaro Sawada, Satoshi Horasawa, Ayumu Yoshikawa, Takao Fujisawa, Shigenori Kadowaki, Tadamichi Denda, Nobuhisa Matsuhashi, Hisateru Yasui, Masahiro Goto, Kentaro Yamazaki, Yoshito Komatsu, Ryota Nakanishi, Yoshiaki Nakamura, Hideaki Bando, Yamato Hamaya, Shun-Ichiro Kageyama, Takayuki Yoshino, Katsuya Tsuchihara, Riu Yamashita
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Colorectal cancer (CRC) is one of the most common malignant diseases. Generally, stoma construction is performed following surgery for the resection of the primary tumor in patients with CRC. The association of CRC with the gut microbiota has been wi
Externí odkaz:
https://doaj.org/article/cdf35b72502c4aafb18359cbff9d7ada
Autor:
Tatsuki Ikoma, Mototsugu Shimokawa, Masahito Kotaka, Toshihiko Matsumoto, Hiroki Nagai, Shogen Boku, Nobuhiro Shibata, Hisateru Yasui, Hironaga Satake
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background RAS/BRAF V600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of pati
Externí odkaz:
https://doaj.org/article/daed111adc22406db03938d47afb31d4
Autor:
Tatsuki Ikoma, Toshihiko Matsumoto, Yusuke Kurioka, Masahiro Takatani, Hiroki Nagai, Yusuke Matsumoto, Hironaga Satake, Hisateru Yasui
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 20, p 6100 (2022)
Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab
Externí odkaz:
https://doaj.org/article/b8b3b948896045b08c229e91291454e7